Antibody Drug Conjugates Contract Market

Antibody Drug Conjugates Contract Market Outlook (2022 to 2032)

The global antibody drug conjugate contract market demand is anticipated to be valued at US$ 9.2 Billion in 2022, forecast a CAGR of 15.5% to be valued at US$ 38.8 Billion from 2022 to 2032. From 2017 to 2021 a CAGR of 12.7% was registered for the antibody drug conjugate contract market.

The global sales of the antibody-drug conjugates contract market in 2021 were held at US$ 8.1 Billion. The antibody-drug conjugates contract market is accounted to give an absolute dollar opportunity growth of nearly US$ 29.7 Billion during 2022 to 2032.

Antibody-drug conjugation (ADC) technology uses monoclonal antibodies (mAbs) to deliver potent, highly active pharmaceutical ingredients (HPAPIs) to targeted cells. In conjugated form, HPAPIs exhibit selective cytotoxicity which can spare non-target cells from toxic effects.

The antibody-drug conjugates contract market is anticipated to gain promising growth owing to the heightening prevalence of cancer around the world during the forecast period 2022 to 2032. As targeted therapy is needed to overcome cancer is necessary as many cancer cases generally result in fatalities.

Antibody-drug conjugate contract is complex powerful biologics that have the potential to treat a wide range of ailments, including cancer. The capacity of these therapies to successfully target disease-associated cells while limiting off-target damage is credited with their clinical potential.

According to the ADC Review, about 70% of ADC projects are outsourced to contract development and manufacturing organizations (CDMOs), and this trend is projected to continue with the pipelines' continuing expansion. As more commercial goods reach the market, CDMOs who understand how to conduct late-stage studies to support the filing strategy is in high demand.

CMOS are setting up systems to address the difficult supply chains and investing in facilities and processes to ensure security, quality, and efficiency in commercial-scale ADC manufacture. As a result of the planned growth in ADC demand, the contract manufacturing market for ADCs is expected to grow significantly in the future years.

Report Attributes	Details
Anticipated Base Year Value (2021)	US$ 8.1 Billion
Expected Market Value (2022)	US$ 9.2 Billion
Projected Forecast Value (2032)	US$ 29.7 Billion
Global Growth Rate (2022 to 2032)	15.5%
Market share of US (2022)	13.7%
CAGR of China (2022 to 2032)	12.6%
Prominent Players in The Global Market	Pantheon; Corden Pharma; Abbvie Inc; Novasep; Merck

Revenue of Antibody Drug Conjugates Contract Market from 2017 to 2021 Compared to Demand Outlook for 2022 to 2032

As per the Antibody Drug Conjugates Contract Market industry research by Fact.MR - market research and competitive intelligence provider, historically, from 2017 to 2021, the market value of the Antibody Drug Conjugates Contract Market industry increased at around 12.7% CAGR, wherein, countries such as the U.S., China, Japan, South Korea, and the UK held a significant share in the global market.

The market for Antibody Drug Conjugates Contract is expected to grow at an immense rate and show some great results in the upcoming years. The global production of antibody-drug conjugates contracts, vaccines, and other pharmaceuticals is expected to increase as a result of the increased demand for effective COVID-19 treatments.

The Antibody Drug Conjugates Contract Market reached a valuation of US$ 8.1 Billion in 2021 and is expected to cross US$ 9.2 Billion mark by the end of 2022.

Top condition type Myeloma is expected to grow with a huge CAGR of 17% during the forecasted period of 2022 to 2032.

From the top application type perspective, Cleavable Linker has shown the CAGR of 12.6% in the historical data and is expected to grow at the rate of 17.2% in the next 10 years.

From the North America region, the United States market size by the end of forecast period is anticipated to be around US$ 7.3 Billion with an absolute dollar growth of US$ 5.3 Billion.

What Market Trends Are Influencing Antibody Drug Conjugates Contract Market Sales?

Growing demand for the biological treatment to boost the antibody-drug conjugates contract market

The growing demand for manufacturing capacity as well as an increasing number of research on antibody therapies to drive the growth of the antibody-drug conjugates contract market during the forecast period.

The Antibody Drug Conjugates Contract Market is predicted to grow significantly throughout the forecast period as a result of subcontracting services and operations to contract manufacturing organizations, increased demand for biologic treatments, and rising cancer occurrences.

With time and research, scientists have enhanced the design and development procedure for these medicines. As a result, four new ADCs will be approved in 2019 and 2020. The US Food and Drug Administration has approved 12 ADCs so far, with another 100 in the works.

Growing prevalence of breast cancer to drive the market growth

The rising application of antibody drug conjugates across breast cancer is anticipated to bring vital growth to the antibody drug conjugates contract market.

Clinical trials for many antibody drug conjugates are in process and are expected to be approved shortly. Thus, this aspect may invite significant growth for the antibody drug conjugates contract market.

For instance, according to the National Cancer Institute estimates that cancer diagnosis is extrapolated to reach approximately 19 mn by 2024. Thus, these factors may bring positive growth for the antibody drug conjugates contract market through the assessment period.

What Are The Current Restraining Factors For The Antibody Drug Conjugates Contract Market?

The growing complexity of the biologic business makes most drugs today made by pharmaceutical companies. This, in turn, has negatively impacted the market for contract manufacturing of antibody drug conjugates.

ADCs are a unique niche in the pharmaceutical industry, with numerous manufacturers executing almost all of the steps, resulting in a high risk of bureaucratic complications. Additionally, since there is about 70 failed clinical trials for ADCs and just a few commercialized products, there is a need to streamline the supply chain to increase productivity.

Comparative View of Addiction Treatment Markets

Antibody Drug Conjugates Contract Market :

Attributes	Antibody Drug Conjugates Contract Market
Growth Factor	The global production of antibody-drug conjugates contracts, vaccines, and other pharmaceuticals is expected to increase as a result of the increased demand for effective COVID-19 treatment.
Opportunity	Increasing prevalence of cancer is expected to provide opportunities for the growth of antibody drug conjugates contract market.

Antibody Drug Conjugates Market :

Attributes	Antibody Drug Conjugates Market
Growth Factor	The rising application of antibody-drug conjugates across breast cancer is anticipated to bring vital growth to the antibody-drug conjugates market.
Opportunity	The escalating prevalence of cancer across the globe bring positive growth for the antibody drug conjugates market through the assessment period.

Antibody Drug Market :

Attributes	Antibody Drug Market
Growth Factor	The rising demand for efficient and effective immunotherapy treatment solutions is positively influencing the trajectory of the global antibody drugs market.
Opportunity	The rising application of monoclonal antibodies in the field of immunotherapy for disorders including cancer, such as oncolytic virus therapy, cancer vaccines, checkpoint inhibitors, and T cell therapy, is one of the major drivers for the development within the global antibody drugs market.

Region-wise Insights

Will Revenue Growth Keep the Momentum High for the North America Antibody Drug Conjugates Contract Market?

Rising Usage in Healthcare Sector Bolstering Sales of the Antibody Drug Conjugates Contract Market in North America

North America dominated the market in terms of revenue in 2022. The increasing prevalence of cancer are the major factors responsible for the dominance of the region. US holds the largest share of North American market.

The US government will be driving the market of U.S. medicinal products through ADC contracts. The projected CAGR for the period from 2017 to 2021 is 13.1%, and from 2022 to 2032 is 13.7%. By 2032, the U.S. leads the market with a projected value of US$ 7.3 Bn.

The growing instances of cancer in the United States, in addition to looking for coping techniques, is raising the interest in ADCs. According to the Centers for Disease Control and Prevention (CDC), 1,708,921 new cancer cases were reported in the US in 2018, with a total of 599,265 deaths. As of May 2021, the Food and Drug Administration (FDA) has approved ten radiopharmaceuticals for treating breast cancer, bladder cancer, multiple myeloma, acute leukemia, and lymphoma.

Why is Asia Pacific Prominent Market for Antibody Drug Conjugates Contract?

Rising prevalence of cancer in the region to boost the market growth

The Asia Pacific led the antibody-drug conjugates contract manufacturing market with a 46.4 % revenue share in 2020. The Asia Pacific accounts for 48% of all new cancer cases worldwide. Out of all the cases, China holds nearly half of the sufferers.

The market for APAC antibody-drug conjugates contract is developing due to the rising frequency of cancer and the growing geriatric population. According to Globocan Data 2020, 52% of cancer patients are 65 or older, and by 2040, this number is expected to quadruple. The most frequent cancer in China is lung cancer, which is followed by stomach, liver, colon, rectum, and breast cancers.

Category-wise Insights

Why Myeloma is Gaining the Utmost Traction when compared with other Condition Types of Antibody Drug Conjugates Contract?

Myeloma is expected to be the highest revenue-generating condition type

The Myeloma segment is the top condition type segment which grew with a CAGR of 13.2% during 2017 to 2021 and is anticipated to bounce and grow with a CAGR of 17% in the forecasted period of 2022 to 2032. This is partly because antibody-drug conjugates contract is a new type of immunotherapy that is now being investigated and evaluated in the treatment of myeloma.

The target site for the monoclonal antibody is the main aggressive component of the monoclonal antibody. As a result, this kind of medication has a very variable effect on damaged cells. As a result, this therapeutic modality is more effective in treating patients suffering from multiple myeloma because it has a rapid onset and broad applicability.

How is Cleavable Linker is more promising application type segment?

Clever linker accounts for highest share of application segment

The most essential aspect affecting the section's expansion is the compensations that cleavable linkers receive in various situations to provide medicine to the object cell. The market segment for cleavable linkers grew with a CAGR of 12.6% during the historical period of 2017 to 2021 is expected to grow with a CAGR of 17.2% during the forecasted period of 2022 to 2032.

Cleavable linkers are the most commonly available kind of ADC linker. The most significant benefit of cleavable linkers is the fact that they are cleaved in response to extracellular and intracellular environments by environmental and lysosomal enzymes.

According to a paper published in April 2019 called "Analysis of key factors related to ADCs structural design," cleavable linkers were used in more than two-thirds of ADCs currently in use in clinical trials.

Start-Ups for Antibody Drug Conjugates Contract Market

The new companies that have started to deal with the various kinds of antibody-drug conjugates contracts have been focussed at employing smart technologies to enhance the productivity as well as efficiency in the field.

Some of the recent developments of Antibody Drug Conjugates Contract Market providers are as follows :

• October 20, 2022 - Catalent, the global leader in enabling biopharma, cell, gene and consumer health partners to optimize development, launch, and supply of better patient treatments across multiple modalities, announced expansion program to increase biologics CGMP analytical capabilities. The additional capacity will increase the capabilities that Catalent has across its network in both standalone services and integrated development programs.

Competitive Landscape

The contract manufacturing industry for antibody drug conjugates is very competitive, with numerous prominent companies. Pantheon, Corden Pharma, Abbvie Inc, Novasep, Merck Lonza group, Cambrex Corporation, Recipharm, Thermo Fisher Scientific, Inc, and Sterling Pharma Solutions are some of the market leaders.

Companies are making significant efforts and capital investments to increase their skills and, as a result, enhance their respective service lineups in order to acquire a competitive advantage. Some companies have built new facilities dedicated to the production of highly powerful chemicals. Various agreements between medication inventors and ADC makers have also been observed in the field.

• In September 2020, Merck announced a EUR 59 million expansion of its ADC manufacturing capabilities at its Wisconsin site. This investment is likely to enable the large-scale production of increasingly effective chemicals for cancer therapy.
• In January 2022, Recipharm announced the purchase of GenIbet to expand its biologics platform.
• In August 2021, Recipharm announced that it has opened a new laboratory to boost its analytical services.
• In July 2021, Lonza Group has extended its relationship with a large biopharmaceutical sector client for the supply of an antibody-drug conjugate against hard-to-treat malignancies.

Market Segments Covered in Antibody Drug Conjugates Contract Market Industry Analysis

• By Condition Type :

  • Myeloma
  • Lymphoma
  • Breast Cancer
  • Other Condition Types

• By Application :

  • Cleavable Linker
  • Non-cleavable Linker

• By Region :

  • North America
  • Latin America
  • Europe
  • APAC
  • MEA